文献速递妇科产科

子宫内膜异位症与绝经期激素治疗影响子宫切除术与卵巢癌的关联

Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
PubMed 文献 · Gynecol Oncol · 2021-11-12

该研究汇总11项病例对照研究数据,纳入5350例卵巢癌患者和7544例无卵巢癌女性,分析子宫切除术与侵袭性上皮性卵巢癌的关联,并按雌激素治疗(ET)和雌孕激素联合治疗(EPT)使用时长及子宫内膜异位症病史分层。结果发现总体及无子宫内膜异位症女性中,子宫切除术与卵巢癌风险呈正关联,但调整ET和EPT使用时长后关联消失;有子宫内膜异位症病史者调整后呈显著负关联。结论认为该关联复杂,需考虑激素治疗时长和子宫内膜异位症病史。

要点

  • 总体及无子宫内膜异位症女性中,子宫切除术与卵巢癌风险呈正关联,调整ET和EPT时长后无显著关联。
  • 有子宫内膜异位症病史女性中,调整ET和EPT时长后子宫切除术与卵巢癌风险呈显著负关联(OR=0.69)。
  • 子宫切除术总体上不具有降低卵巢癌风险的作用,但子宫内膜异位症女性的负关联需进一步研究。

核心结论

  • 子宫切除术与卵巢癌的关联复杂,需考虑ET和EPT使用时长及子宫内膜异位症病史。
  • 总体而言,子宫切除术不具有降低卵巢癌风险的作用,但子宫内膜异位症女性的负关联需进一步研究。

研究设计与样本

  • 卵巢癌协会联盟(OCAC)11项病例对照研究的汇总分析,纳入5350例卵巢癌患者和7544例无卵巢癌女性。
  • 纳入从未使用激素治疗或仅使用ET或EPT的女性,按ET和EPT使用时长调整,并按子宫内膜异位症病史分层。

主要发现

  • 总体女性中,子宫切除术与卵巢癌风险呈正关联(OR=1.19,95%CI 1.09-1.31),调整ET和EPT时长后无显著关联(OR=1.04,95%CI 0.94-1.16)。
  • 无子宫内膜异位症女性中,子宫切除术与卵巢癌风险呈正关联(OR=1.20,95%CI 1.09-1.32),调整后无显著关联(OR=1.06,95%CI 0.95-1.18)。
  • 有子宫内膜异位症病史女性中,子宫切除术与卵巢癌风险呈轻微负关联(OR=0.93,95%CI 0.69-1.26),调整ET和EPT时长后负关联增强且具统计学显著性(OR=0.69,95%CI 0.48-0.99)。

关键数值与推荐

  • 总体女性子宫切除术与卵巢癌风险OR=1.19(95%CI 1.09-1.31),调整后OR=1.04(95%CI 0.94-1.16)。
  • 无子宫内膜异位症女性子宫切除术与卵巢癌风险OR=1.20(95%CI 1.09-1.32),调整后OR=1.06(95%CI 0.95-1.18)。
  • 有子宫内膜异位症病史女性子宫切除术与卵巢癌风险OR=0.93(95%CI 0.69-1.26),调整后OR=0.69(95%CI 0.48-0.99)。

临床怎么用

  • 评估子宫切除术与卵巢癌关联时,应考虑ET和EPT使用时长及子宫内膜异位症病史。
  • 子宫切除术总体上不具有降低卵巢癌风险的作用。
  • 子宫内膜异位症女性的负关联需进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association. METHODS: We conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer Association Consortium (OCAC). Women with (n = 5350) and without ovarian cancer (n = 7544) who never used HT or exclusively used either estrogen-only therapy (ET) or estrogen+progestin therapy (EPT) were included. Risk of invasive epithelial ovarian cancer adjusted for duration of ET and EPT use and stratified on history of endometriosis was determined using odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: Overall and among women without endometriosis, there was a positive association between ovarian cancer risk and hysterectomy (OR = 1.19, 95% CI 1.09-1.31 and OR = 1.20, 95% CI 1.09-1.32, respectively), but no association upon adjusting for duration of ET and EPT use (OR = 1.04, 95% CI 0.94-1.16 and OR = 1.06, 95% CI 0.95-1.18, respectively). Among women with a history of endometriosis, there was a slight inverse association between hysterectomy and ovarian cancer risk (OR = 0.93, 95% CI 0.69-1.26), but this association became stronger and statistically significant after adjusting for duration of ET and EPT use (OR = 0.69, 95% CI 0.48-0.99). CONCLUSIONS: The hysterectomy-ovarian cancer association is complex and cannot be understood without considering duration of ET and EPT use and history of endometriosis. Failure to take these exposures into account in prior studies casts doubt on their conclusions. Overall, hysterectomy is not risk-reducing for ovarian cancer, however the inverse association among women with endometriosis warrants further investigation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Khoja L, Weber RP, Webb PM, et al. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecol Oncol. 2021. PMID: 34776242. doi:10.1016/j.ygyno.2021.10.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。